All patients treated eye | Patients with best seeing eye treated | Patients with worst seeing eye treated | ||||||||||
B | 3 m | 6 m | 12 m | B | 3 m | 6 m | 12 m | B | 3 m | 6 m | 12 m | |
BCVA logMAR treated eye Fractional | 0.59 20/78 | 0.44** 20/55 | 0.38** 20/48 | 0.34** 20/44 | 0.39 20/49 | 0.33 20/43 | 0.28* 20/38 | 0.32 20/42 | 0.69 20/94 | 0.48** 20/60 | 0.42** 20/53 | 0.35** 20/45 |
NEI-VFQ-25 | 79.7 | 82.2** | 82.6** | 82.1* | 71.0 | 76.9** | 76.4** | 76.1* | 83.0 | 84.2 | 84.9 | 84.4 |
PASS 5 | 3.3 | 2.8** | 2.7** | 2.8** | 3.6 | 2.9** | 2.9** | 3.0** | 3.2 | 2.8** | 2.6** | 2.7** |
EQ-5D | 0.74 | 0.73 | 0.76 | 0.77 | 0.68 | 0.69 | 0.73 | 0.74 | 0.77 | 0.74 | 0.77 | 0.78 |
DITAMD management | NA | 8.3 | 8.4 | 7.9 | NA | 8.2 | 8.4 | 7.9 | NA | 8.3 | 8.4 | 7.9 |
Bold denotes significant change from baseline: **p < 0.001 and *p < 0.05.
B, baseline;DITAMD, Dimensions of Importance in Treatment of neovascular Age-related Macular Degeneration; EQ-5D, EuroQol Group Questionnaire; 6m, 6 months;12m, 12 months; 3 m, 3 months;NA, Not applicable; NEI-VFQ-25, National Eye Institute Visual-Functioning-Questionnaire-25.